Top 10 Drugs: Biologic Blockbusters And The Biosimilar Threat
INFOGRAPHIC: maturing cancer and autoimmune biologics still top the league for global revenues, but biosimilars are snapping at their heels.
You may also be interested in...
Amgen and Allergan have announced positive top-line results from a pivotal clinical study of their rituximab biosimilar version of Roche’s blockbuster biologic Rituxan to treat patients with non-Hodgkin's lymphoma.
Sandoz expects to bring an expedited appeal against a US district court’s finding that two patents protecting Amgen’s Enbrel etanercept brand until 2028 and 2029 are valid.
INFOGRAPHIC: A relatively small number of relatively costly drugs account for a sizable proportion of pharma industry revenues. But what are its biggest golden eggs, how reliant are companies on those products, and how has the situation evolved over time?